Whalen Wealth Management Inc. Has $790,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Whalen Wealth Management Inc. decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 28.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,024 shares of the company’s stock after selling 398 shares during the quarter. Whalen Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $790,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the business. Avior Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 8.6% in the fourth quarter. Avior Wealth Management LLC now owns 5,253 shares of the company’s stock worth $4,056,000 after purchasing an additional 414 shares during the last quarter. Beacon Investment Advisory Services Inc. lifted its stake in Eli Lilly and Company by 41.0% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 28,122 shares of the company’s stock valued at $21,710,000 after acquiring an additional 8,172 shares in the last quarter. Peterson Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 12.2% in the 4th quarter. Peterson Wealth Advisors LLC now owns 803 shares of the company’s stock worth $628,000 after acquiring an additional 87 shares in the last quarter. MinichMacGregor Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 25.3% during the fourth quarter. MinichMacGregor Wealth Management LLC now owns 915 shares of the company’s stock valued at $707,000 after purchasing an additional 185 shares in the last quarter. Finally, Raleigh Capital Management Inc. boosted its stake in shares of Eli Lilly and Company by 14.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,295 shares of the company’s stock worth $1,000,000 after buying an additional 159 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.4 %

LLY stock opened at $784.78 on Friday. Eli Lilly and Company has a one year low of $624.68 and a one year high of $972.53. The company has a market capitalization of $745.01 billion, a PE ratio of 84.84, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41. The company’s 50 day moving average price is $776.69 and its two-hundred day moving average price is $849.41. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a $1.50 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company declared that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LLY shares. Citigroup boosted their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price for the company. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,002.22.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.